Press Releases

November 18, 2020
Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314

June 23, 2020
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

August 27, 2019
Pionyr Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages

July 10, 2018
Pionyr Immunotherapeutics and ProBioGen Initiate a Second Immuno-Oncology Contract Development and Manufacturing Project

December 13, 2017
Pionyr Immunotherapeutics Completes $62 million Series B Financing to Advance Antibody-Based Therapeutics Targeting the Tumor Microenvironment

January 4, 2017
Pionyr Immunotherapeutics Closes Financing with Focus on Developing Antibody-based Immuno-oncology Therapeutics